ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
A case of autoimmune cerebellar ataxia associated with anti-neurochondroitin antibody.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune cerebellar ataxia (ACA) is a complex neurological disorder characterized by immune-mediated damage to the cerebellum, which gives rise to ataxia symptom. Auto-neuronal antibodies play a crucial role in the diagnosis of ACA. We present a case of an early 70s male whose main presenting symptom was subacute cerebellar ataxia. Enhanced cranial magnetic resonance imaging (MRI) did not detect any significant cerebellar lesions. The serum anti-neurochondroitin (NCDN) antibody IgG titer was 1:320, while the cerebrospinal fluid anti-NCDN antibody IgG titer was 1:1. After the administration of intravenous immunoglobulin (IVIG) and glucocorticoids, the patient’s symptoms were rapidly relieved. During a six-month follow-up period, the patient’s condition did not recur and it was maintained with low-dose oral glucocorticoids. Threrfore, It is recommended that auto-neurologic antibody testing be included into the routine diagnostic process for patients suspected of having ACA to enable early diagnosis. Early initiation of immunotherapy may significantly improve the prognosis of ACA patients.
Indexed as
Identifiers
41973249What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.